Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

BackgroundBrain metastases (BM), including brain parenchyma metastases (BPM) and leptomeningeal metastases (LM), are devastating metastatic complications in advanced cancer patients. Next-generation sequencing (NGS) is emerging as a new promising tool for profiling cancer mutation, which could facil...

Full description

Bibliographic Details
Main Authors: Xiaocui Liu, Fengjun Mei, Mei Fang, Yaqiong Jia, Yazhu Zhou, Chenxi Li, Panpan Tian, Chufan Lu, Guangrui Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer (NSCLC)
leptomeningeal metastases (LM)
brain parenchyma metastases (BPM)
cerebrospinal fluid circulating tumour DNA (ctDNA)
next generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1322635/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1322635/full

Similar Items